COEP
Coeptis Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.99
−8.57%Year over year
Reported trailing growth
- Revenue
- +2148.9%
- EBITDA
- -9.4%
- EBIT
- -15.3%
- EPS
- —
- Free cash flow
- -12.4%
- Operating cash flow
- -12.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -11.0%
- EBIT
- -29.7%
- Net income
- -11.6%
- EPS
- +50.3%
- Free cash flow
- -29.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026